priors.science/reviews/glp-1-receptor-agonists

GLP-1 Receptor Agonists

The current evidence on 35 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty: how firmly the literature supports the claim as stated.

39claims tracked
35assessed
607primary papers reviewed
21 Oct 2026latest evidence review
Overall grades reviewedby 3 independent experts · Oct 2026 · release 2026-q4
6 Established · 8 Likely · 15 Uncertain · 5 Doubtful · 1 Refuted  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Reduce major adverse cardiovascular events in type 2 diabetes with established cardiovascular diseaseCardiovascularEstablished90%27
Tirzepatide outperforms single GLP-1 receptor agonistsMetabolicEstablished89%20
Semaglutide 2.4 mg achieves 15% body weight lossMetabolicEstablished88%21
Improve non-alcoholic fatty liver diseaseMetabolicEstablished87%21
Tirzepatide 15 mg achieves 20% body weight lossMetabolicEstablished86%20
Reduce obstructive sleep apnoeaNovelEstablished86%21
Reduce all-cause mortality in type 2 diabetesCardiovascularLikely84%22
Renal protection and slower chronic kidney disease progressionMetabolicLikely84%20
Cardiovascular benefit in non-diabetic obesityCardiovascularLikely80%23
No increase in suicidalitySafetyEarly evidenceLikely80%30
No overall gastrointestinal cancer increaseCancerLikely78%19
Reduce alcohol consumptionAddictionLong-standingLikely77%22
Reduce atrial fibrillation recurrenceCardiovascularLikely72%21
Increase non-arteritic anterior ischaemic optic neuropathy riskSafetyLikely72%31
Reduce neuroinflammation (microglial suppression)NeurodegenerationLong-standingUncertain65%19
Improve polycystic ovary syndrome fertilityNovelUncertain63%19
Reduce peripheral arterial disease and limb eventsCardiovascularUncertain62%21
Improve psoriasis severityNovelUncertain62%16
Modulate reward circuitryAddictionLong-standingUncertain60%20
Reduced colorectal cancer riskCancerUncertain60%15
Reduce heart failure hospitalisationCardiovascularUncertain60%23
Reduce Alzheimer's disease riskNeurodegenerationEarly evidenceUncertain60%18
Reduce nicotine cravingsAddictionUncertain58%23
Bone density and fracture riskSafetyUncertain58%18
Improve male reproductive functionNovelUncertain55%18
Reduce fibromyalgia symptomsNovelEarly evidenceUncertain55%17
Tirzepatide has better ocular safetySafetyEarly evidenceUncertain55%16
Worsen diabetic retinopathySafetyUncertain54%18
Increase gallbladder disease riskSafetyUncertain50%19
Reduce opioid and stimulant useAddictionDoubtful45%21
Clinically significant lean mass lossSafetyEarly evidenceDoubtful44%20
Sustained heart rate increase of 2-4 beats per minuteSafetyLong-standingDoubtful42%17
Improve breast cancer disease-free survivalCancerDoubtful35%19
Slow Parkinson's disease progressionNeurodegenerationLong-standingDoubtful35%19
Improve cognition in established Alzheimer's diseaseNeurodegenerationRefuted14%19
Track GLP-1 Receptor Agonists.
These claims are re-checked against new research as it is published. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing: what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it. Confidently false as stated.
A standing changes only when the score moves past a boundary by more than 4 points, the re-scoring noise floor; a score within 4 points of a boundary keeps its previous standing.
Where the evidence sits in time
Early evidenceMost of this evidence is from the last two years.
Long-standingMost of this evidence is older than the rest of this field.